- CEO
- Satian Pooprasert
- Full Time Employees
- 1,558
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- 99, Rama IX Road Bangkok BM Thailand 10310
- IPO Date
- Oct 30, 2018
- Business
- Praram 9 Hospital Public Company Limited (PR9.BK) operates a multispecialty hospital in Bangkok, Thailand, providing comprehensive healthcare services to both Thai and international patients. Founded in 1992 and headquartered at 99 Rama IX Road, Bangkapi, Huai Khwang, Bangkok, the company offers outpatient and inpatient care across numerous centers and institutes, including medicine; surgery; diabetes and metabolic; spine; orthopedic; physical therapy and rehabilitation; chest and respiratory; neurology; thyroid and thyroid surgery; obstetrics gynecology; IVF; breast; oncocare; emergency; imaging; Lasik; skin and plastic surgery; mind; gastrointestinal and liver disease; dental; check-up; eye; pediatric; sleep; ear, nose, and throat; vaccination and travel medicine; and traditional Chinese medicine clinics; as well as the Praram 9 Kidney Transplantation Institute, Praram 9 Cardiovascular Institute, and pain management and wellness services. The hospital serves primarily self-pay and insurance patients, with a growing focus on international markets such as the Middle East, Laos, Cambodia, and CLMV countries, alongside Thai domestic customers. In recent developments, Praram 9 Hospital received the Collaboration Silver Award from Muang Thai Life Assurance Public Company Limited for enhanced healthcare partnerships; partnered with Cariva's (Thailand) Co., Ltd. to introduce 53-gene genetic testing for cancer risk assessment; earned SET Awards 2025 for Sustainability Excellence and Outstanding Investor Relations, Bangkok Life Hospital Awards 2025 for medical management excellence, and three IAA Awards for Listed Companies 2025; collaborated with AIS on e-waste management initiatives; and reported strong financial growth in the first half of 2024 with total revenues up 9.8% to Baht 2,178.0 million and net profit up 29.7% to Baht 298.1 million, driven by increased international and insurance patient volumes, OPD/IPD expansions, and marketing efforts targeting fly-in patients. The company continues to invest in brand awareness, facility renovations, cost management, and financial assets for higher returns while maintaining a debt-to-equity ratio of 0.2 times.